Sort by
Refine Your Search
-
Listed
-
Field
-
Pal, please visit here . For a complete list of Dr. Pal’s publications please visit here . As a successful candidate you will: · Develop and maintain clinical and translational research trials
-
models to study metabolic diseases is preferred. For a complete list of Publications please visit here: https://www.ncbi.nlm.nih.gov/myncbi/1J54E41I5YVku/bibliography/public/ Your qualifications should
-
of adipose tissue and its link to age-related metabolic disorders and cancer. Ultimately, we aim to mitigate the pathogenesis and develop treatments for chronic metabolic diseases. We have established unique
-
, Cancer Biology, Chromatin Regulation, Cancer Epigenetics, Epigenetics Regulation, Cancer Metabolism, Immunology, Drug Discovery, Development, and Structural Biology, with an emphasis on RNA epigenetics
-
the Department of Hematological Malignancies Translational Science, Department of Pediatrics, and Gehr Family Center for Leukemia Research. You will directly work on the following projects: 1) Development
-
successful candidate, you will: This project with Dr. Nagarajan Vaidehi involves developing and application of interpretable machine learning methods to uncover allosteric regulation of disordered regions in
-
Hope. To accelerate the development of new therapies, we leverage City of Hope’s unique in-house GMP manufacturing capabilities for cell therapy (CAR-T cells, stem cells, etc.), monoclonal antibodies
-
visit here . If you are passionate about some of the following things we are working on this may be the perfect opportunity: · Development of cell-free DNA (mutation and methylation), RNA, and
-
discovery approaches and biochemical assays to target key proteins. This funded position is for a postdoctoral trainee interested in aiding the development of novel therapeutics for treating cancer
-
studies. The lab focuses on mechanisms underlying human T-cell development and lymphoid leukemogenesis and the application of these mechanistic insights to the development of novel anti-cancer immunotherapy